Subscribe to our Newsletters !!
A team of scientists from the Singapore-MIT Allian
Purified water is housed in an intermediate storag
High blood pressure is one of the most important r
Kiran Mazumdar-Shaw, Executive Chairperson of Bioc
Mumbai, India, 14th September: Cipla Li
Following the success of the promotion and informa
Tabernanthe iboga (iboga) is an indigenous plant i
4th May 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Docosanol Cream, 10% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Abreva Cream, 10% (OTC), of GlaxoSmithKline Consumer Healthcare. Docosanol Cream, 10% (OTC) is used for cold sore/fever blisters on the face or lips.
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA.
Alembic has received a cumulative total of 166 ANDA approvals (142 final approvals and 24 tentative approvals) from USFDA.
